2012 European guideline on the diagnosis and treatment of gonorrhoea in adults

C Bignell MBBS FRCP*, M Unemo PhD† on behalf of the European STI Guidelines Editorial Board (Keith Radcliffe [Editor-in-Chief], Jørgen Skov Jensen [Gonorrhoea Guideline Editor], Karen Babayan, Simon Barton, Marco Cusini, Mikhail Gomberg, Michel Janier, Lali Khotenashvili, Harald Moi, Martino Neumann, Raj Patel, Jonathan Ross, Jackie Sherrard, George-Sorin Tiplica, Magnus Unemo, Marita van de Laar, Willem van der Meijden)

*City Hospital Campus, Nottingham University Hospitals NHS Trust, Hucknall Road, Nottingham NG 1PB, UK; †WHO Collaborating Center for Gonorrhoea and other Sexually Transmitted Infections, National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, SE-701 85 Örebro, Sweden

Summary: Gonorrhoea is a major public health concern globally. Of particularly grave concern is that resistance to the extended-spectrum cephalosporins has emerged during the most recent years. This guideline provides recommendations regarding the diagnosis and treatment of gonorrhoea in Europe. Compared to the outdated 2009 European gonorrhoea guideline, this 2012 European gonorrhoea guideline provides up-to-date guidance on, broader indications for testing and treatment of gonorrhoea; the introduction of dual antimicrobial therapy (ceftriaxone 500 mg and azithromycin 2 g) for uncomplicated gonorrhoea when the antimicrobial sensitivity is unknown; recommendation of test of cure in all gonorrhoea cases to ensure eradication of infection and identify emerging resistance; and recommendations to identify, verify and report failures with recommended treatment regimens. Optimisations of the testing, diagnostics, antimicrobial treatment and follow-up of gonorrhoea patients are crucial in controlling the emergent spread of cephalosporin-resistant and multidrug-resistant gonorrhoea.

Keywords: gonorrhoea, European clinical guideline, management, Neisseria gonorrhoeae, diagnosis, antimicrobial resistance, antimicrobial treatment, antibiotic

AETIOLOGY AND TRANSMISSION

- Gonorrhoea (meaning ‘flow of seed’ in old Greek) and its related clinical manifestations are caused by infection with the Gram-negative bacterium Neisseria gonorrhoeae;
- Infection predominantly involves the columnar epithelium of the urethra, endocervix, rectum, pharynx and conjunctivae. Although it usually remains localized to the initial sites of infection, it can ascend to the upper genital tract to cause pelvic inflammatory disease (PID) and epididymo-orchitis or disseminate as bacteraemia;
- Transmission is by direct inoculation of infected secretion from one mucosa to another, i.e. genital–genital, genital–anorectal, oro-genital or oro-anal contact or by mother-to-child transmission at birth;
- In 2008, the World Health Organization (WHO) estimated 106 million cases of gonorrhoea among adults globally, a similar global incidence to genital chlamydial infections. In Europe, gonorrhoea is the second most common bacterial sexually transmitted infection (STI), i.e. after chlamydial infections. However, the incidence in several countries is underestimated because of suboptimal diagnostics, case reporting and surveillance. There is considerable geographic variation in the distribution of gonorrhoea and infection is reported three times more frequently in men than in women, reflecting the significantly higher proportion of symptoms in men and the burden of infection in men who have sex with men (MSM). The highest incidence of gonorrhoea is in young adults (15–29 years) and, in many countries, there is a disproportionate burden of disease in ethnic minority groups and MSM.1–4

CLINICAL FEATURES

Symptoms and physical signs of gonorrhoea commonly reflect localized inflammation of infected mucosal surfaces in the genital tract.5–8

Symptoms

- In men, the predominant presentation is of acute urethritis with symptoms of urethral discharge (>80%) and dysuria (>50%), usually starting within 2–8 days of exposure. Asymptomatic urethral infection is uncommon in men (less than 10% of urethral infections);
In women, genital tract symptoms relate to endocervical and urethral infection and include increased or altered vaginal discharge (≤50%), lower abdominal pain (≤25%), dysuria (10–15%) and rarely intermenstrual bleeding or menorrhagia. Endocervical infection is commonly asymptomatic (≥50%);

- Rectal and pharyngeal infections are usually asymptomatic.9,10

**Physical signs**

- In men, the most common finding on examination is a mucopurulent urethral discharge, which may be accompanied by erythema of the urethral meatus;
- In women, examination may be normal or a mucopurulent discharge may be evident from the cervix, sometimes accompanied with hyperaemia and contact bleeding of the endocervix.

**Complications**

PID in women and epididymo-orchitis in men are the most notable complications from local spread of gonococcal infection. Gonococcal bacteremia rarely occurs (less than 1% of infections) and is usually manifested by skin lesions, fever, arthralgia, acute arthritis and tenosynovitis (disseminated gonococcal infection [DGI]).5,11,12

**DIAGNOSIS**

- The diagnosis of uncomplicated gonorrhoea is established by identification of *N. gonorrhoeae* in genital, rectal, pharyngeal or ocular secretions;
- *N. gonorrhoeae* can be detected by nucleic acid amplification tests (NAATs) or culture. The bacterium can also be visualized on microscopy of a stained genital tract smear to facilitate rapid diagnosis in symptomatic patients. No test offers 100% sensitivity and specificity;
- Microscopy (×1000) using Gram or methylene blue staining for identification of diplococci within polymorphonuclear leukocytes offers good sensitivity (≥95%) and specificity as a rapid diagnostic test in symptomatic men with urethral discharge (level of evidence III; grade C recommendation).3,6,13 Microscopy has poor sensitivity (≤55%) in asymptomatic men and in identifying endocervical (≤55%) or rectal infection (≤40%) and cannot be recommended as a test of exclusion in these situations [III; C].3,6,8 Microscopy is not recommended for identification of pharyngeal infection due to poor specificity as well as low sensitivity;
- Culture offers a specific and cheap diagnostic test that readily allows confirmatory identification. It is the only diagnostic test that enables antimicrobial susceptibility testing and capacity to perform culture remains essential to detect and monitor evolving antimicrobial resistance. Selective culture media containing antimicrobials are recommended [III; B].14 Non-selective media can beneficially be used in addition to the selective media for urogenital and conjunctival samples if affordable. Culture is appropriate for endocervical, urethral, rectal, pharyngeal and conjunctival specimens but not for urine. The sensitivity of culture is high for genital samples, providing that specimen collection, transport, storage and isolation procedures are optimized.

An appropriate quality assurance is needed for the gonorrhoea culture system since commercial media and culture procedures vary in their selectivity and sensitivity. Culture (ideally supplemented with a NAAT for optimal diagnostic sensitivity) should be performed for antimicrobial sensitivity testing in patients with persisting infection or symptoms following treatment or if treatment failure is suspected.15,16 NAATs are more sensitive than culture, offer testing on a wider range of specimen types and are less demanding in specimen quality, transportation and storage.17–23 They show high sensitivity (>96%) in both symptomatic and asymptomatic infections, show equivalent sensitivity in urine and urethral swab specimens from men24 and equivalent sensitivity in clinician-taken or self-taken vulvo-vaginal and endocervical swabs from women.24 NAATs significantly outperform transported samples for culture and are the sample of choice for testing individuals who are asymptomatic.17,18 In women, urine samples offer a lower sensitivity than swabs from the genital tract and are not the optimal sample for testing [II; B].17,20,21,25 The performance characteristics of different commercially available or in-house gonococcal NAATs differ substantially, particularly in regard to specificity;

- When using NAATs to detect *N. gonorrhoeae*, the positive predictive value (PPV) of the testing protocol used should exceed 90%. The principal factors influencing the PPV are the prevalence of gonorrhoea in the population tested and variation in the specificity of available NAATs, particularly at non-genital sites. If the used diagnostic NAAT does not display a PPV exceeding 90%, positive samples are recommended to be subjected to confirmatory testing, i.e. repeated with a NAAT targeting another sequence [III; B].26–28 NAATs are significantly more sensitive than culture for detecting pharyngeal and rectal infection29–35 and are the test of choice for screening for rectal and pharyngeal gonococcal infections. However, commercially available NAATs are not licensed for testing specimens from these sites and they differ significantly in their specificity.36,37 particularly at the pharynx due to the frequent presence of non-gonococcal *Neisseria* species. It is recommended that strict local evaluation is performed before introducing a NAAT to test rectal and pharyngeal samples. When used after evaluation, confirmatory testing is recommended, i.e. repeated with a NAAT targeting another sequence [IIb; B].18,27,28

- Women may have genital tract infection localized to the endocervix or urethra. In the current era of NAAT testing, asymptomatic women are commonly offered screening for gonorrhoea and chlamydial infection by a single vulvo-vaginal or endocervical test.30 This pragmatic approach is endorsed although there remains a lack of evidence to confirm its effectiveness in excluding gonorrhoea [IV, C]. The additional contribution of routinely testing rectal and pharyngeal sites when screening women for gonorrhoea is poorly defined in Europe, although sampling these sites should be considered when there is a history of direct exposure [IV, C].30 Evidence on the minimum incubation period necessary before testing can be recommended is lacking, although clinical experience suggests that positive NAAT results may be observed within 1–2 days of infection;

- A minority of MSM with gonorrhoea (20–30%) have infection at multiple sites.9,30 Tests should be taken from the
urethra/urine, rectum and pharynx as directed by sexual practices.

Indications for testing [IV; C]

- Symptoms or signs of urethral discharge in men;
- Vaginal discharge with risk factor for STI (age <30 years, new sexual partner);
- Mucopurulent cervicitis;
- Persons diagnosed with any other STI;
- Sexual partner of persons with an STI or PID;
- Acute epididymo-orchitis in a male aged <40 years;
- Acute PID;
- When screening young adults (<25 years of age) for STI;
- When screening individuals with new or multiple recent sexual partners;
- Purulent conjunctivitis in a neonate or adult;
- Mother of a newborn with ophthalmia neonatorum.

MANAGEMENT OF PATIENT

Information, explanation and advice for the patient

- Patients should be advised to abstain from sexual contact for seven days after they and their partners have completed treatment and their symptoms have resolved [IV; C];
- Patients (and their sex partners) should be given information about their infection, including details about transmission, prevention and complications. It is recommended that both verbal and written information be provided [IV; C];
- A patient information leaflet is available on the IUSTI – Europe website for guidelines (http://www.iusti.org/regions/Europe/euroguidelines.htm).

Therapy

_N. gonorrhoeae_ has shown a remarkable capacity to develop resistance to multiple classes of antibiotics including penicillins, tetracyclines, macrolides and fluoroquinolones. After a steady rise in minimum inhibitory concentrations (MICs) in recent years, resistance and even clinical failures to extended-spectrum cephalosporins (ceftriaxone and cefixime) have now been confirmed. In this emergent situation, including the fear that gonorrhoea may become untreatable, the WHO has published the ‘Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in _Neisseria gonor- rhoeae_.’ The European Centre for Disease Prevention and Control (ECDC) has published the ‘Response Plan to Control and Manage the Threat of Multidrug-Resistant Gonorrhoea in Europe’ and the Centers for Disease Control and Prevention (CDC) has also launched a public health response plan for the USA. Ceftriaxone and cefixime have a strong evidence-base for efficacy in the treatment of gonorrhoea and were the principal recommended treatments in the 2009 guideline. As a consequence of the emergence of clinically important resistance to extended-spectrum cephalosporins and the absence of robust alternative antimicrobials that can be administered as a single dose, these guidelines have adopted combination antimicrobial therapy as a strategy to delay and combat the widespread development of multidrug resistance rather than only recommending administration of an increased dose of the extended-spectrum cephalosporin. According to limited data, combination antimicrobial therapy with extended-spectrum cephalosporins and azithromycin seems to show synergy in vitro and in vivo, and also eradicates concomitant _Chlamydia trachomatis_ infection, which is relatively common in many settings. Published clinical trials on the treatment of gonorrhoea do not address the rapidly evolving situation of resistance to extended-spectrum cephalosporins and provide very limited data on the treatment of multidrug resistant gonorrhoea. Treatment regimens recommended in this guideline are based on early clinical efficacy trials, pharmacokinetic/pharmacodynamic considerations, in vitro antimicrobial susceptibility surveillance data, and case reports of antimicrobial resistance and anticipated trends in antimicrobial resistance. Nevertheless, there remains significant geographical variation in resistance and local alternative treatments based on comprehensive, quality assured local surveillance data of resistance may be reasonable.

Indications for therapy [IV; C]

- Identification of intracellular diplococci at a genital site by Gram stain or Methylene blue-stain microscopy;
- Positive culture or confirmed NAAT from any site for _N. gonorrhoeae_ (or unconfirmed NAAT from urogenital specimens in settings where PPV >90%);
- On epidemiological grounds, if a recent partner has confirmed gonococcal infection;
- On epidemiological grounds, mother of neonate with confirmed gonococcal infection;
- On epidemiological grounds, treatment can be considered following sexual assault;
- On demonstration of a purulent urethral discharge in men or mucopurulent cervicitis in women when rapid diagnostic tests are not available and after specimen collection for laboratory testing. In this circumstance, combined treatment for gonococcal and chlamydial infection should always be given.

Recommended treatments for uncomplicated _N. gonorrhoeae_ infections in the urethra, cervix and rectum in adults and adolescents when the antimicrobial sensitivity of the infection is unknown

Ceftriaxone 500 mg intramuscularly as a single dose together with azithromycin 2 g as single oral dose [IV; C].

**NOTE:** Azithromycin tablets may be taken with or without food but gastrointestinal side-effects can be less if taken after food. If ceftriaxone 500 mg for intramuscular injection is not available, the intramuscular suspension can be mixed as follows: 3.5 mL of 10 mg/mL (1%) lidocaine without adrenaline is suspended into a 1 g vial of ceftriaxone and mixed. Two millilitres of the mixture is drawn and injected intramuscularly.

Alternative regimens

1. Cefixime 400 mg oral as a single dose [Db; A] together with azithromycin 2 g as a single oral dose [IV; C]. This regimen is only an alternative option if ceftriaxone is not available or administration of injectable antimicrobials is not possible or refused by the patient.
2. Ceftriaxone 500 mg intramuscularly as a single dose [IV; C]. This regimen is only an alternative option if azithromycin is not available or patient is unable to take oral medication.
3. Spectinomycin 2 g intramuscularly as a single dose [Db; A] together with azithromycin 2 g as a single oral dose
Single-dose fluoroquinolone regimens

Cefixime 400 mg has been widely used as an oral single dose treatment for gonorrhoea. Multiple recent reports of treatment failures and pharmacodynamic investigations have raised serious concerns over the adequacy of 400 mg of cefixime as a single dose treatment.42,44–47,49 Cefixime is only an alternative option if administration of an intramuscular injection is not possible or refused by the patient. However, caution should be taken using cefixime 400 mg only, particularly for treatment of pharyngeal infection, and ideally, if used, it should always be given together with azithromycin 2 g as a single oral dose (see alternative regimen 1 above).

Alternative injectable or oral cephalosporins offer no advantage in terms of efficacy and pharmacokinetics/pharmacodynamics over ceftriaxone or cefixime, and treatment efficacy for pharyngeal infection is less certain. Accordingly, alternative cephalosporins cannot be recommended.56–61

• Single-dose fluoroquinolone regimens

Fluoroquinolones cannot generally be recommended for the treatment of gonorrhoea because of the worldwide high prevalence of quinolone resistance.3,40,41,50 When an infection is known before treatment to be fluoroquinolone sensitive, based on appropriate laboratory susceptibility testing and there are indications against using ceftriaxone, ciprofloxacin 500 mg oral as a single dose or ofloxacin 400 mg oral as a single dose have proven high efficacy [IIb; A].56,62

• Azithromycin

Clinical trials have demonstrated that azithromycin has high efficacy (>98%) as a single oral 2 g dose.63,64 However, it is not recommended for the treatment of gonorrhoea unless there is a history of penicillin anaphylaxis or cephalosporin allergy and, ideally, infection is proven before treatment to be azithromycin sensitive. High levels of azithromycin resistance and treatment failures have been observed in Europe43,65–69 and clinical outcome does not always correlate with in vitro sensitivity.70

Therapy for uncomplicated gonococcal infection of the pharynx

Many antimicrobials have demonstrated lower efficacy (<90%) in eradicating N. gonorrhoeae from the pharynx than in eradicating genital and anorectal infection.56,60,71,72 This correlates with the pharmacokinetic properties of the individual antimicrobials. Treatment with spectinomycin has poor efficacy at eradicating pharyngeal gonorrhoea.40,56–60

Recommended treatment for pharyngeal infection

Ceftriaxone 500 mg intramuscularly as a single dose together with azithromycin 2 g oral single dose [IV; C].

Alternative regimens

Ceftriaxone 500 mg intramuscularly as a single dose [IV; C]. This regimen is only an alternative option if azithromycin is not available or patient is unable to take oral medication.

Alternative treatments for pharyngeal infection when there is a history of penicillin anaphylaxis or cephalosporin allergy and fluoroquinolone or azithromycin resistance are excluded by appropriate laboratory susceptibility testing:

• Ciprofloxacin 500 mg as a single oral dose or ofloxacin 400 mg as a single oral dose or azithromycin 2 g as a single oral dose.

Therapy of gonococcal infections in pregnancy or when breastfeeding

Recommended treatment:77

Ceftriaxone 500 mg intramuscularly as a single dose [Ib; A].

Alternative regimen

Spectinomycin 2 g intramuscularly as a single dose (has poor efficacy for treatment of pharyngeal gonorrhoea).40,56–60

The safety of azithromycin in pregnancy has not been confirmed but clinical experience indicates that it may be safely used. It should only be used under medical supervision if the expected benefit to the mother is thought to be greater than the possible risk to the fetus.78 Azithromycin passes into breast milk and is not recommended while breastfeeding. Pregnant and breastfeeding women should not be treated with fluoroquinolone or tetracycline antimicrobials.

Therapy of gonococcal infections in patients with penicillin allergy

Third-generation cephalosporins show negligible cross-allergy with penicillins and allergy to these cephalosporins is rare.79,80 If allergy is not excluded and third-generation cephalosporins still need to be given, the patient should be under medical supervision for at least 30 minutes.
Recommended treatment for patients with a history of penicillin anaphylaxis or cephalosporin allergy:

Spectinomycin 2 g intramuscularly as a single dose [Ib; A] together with azithromycin 2 g oral single dose.

Alternative treatments in patients with known penicillin anaphylaxis or cephalosporin allergy when fluoroquinolone or azithromycin sensitivity has been confirmed by appropriate laboratory susceptibility testing:

- Ciprofloxacin 500 mg oral as a single dose or ofloxacin 400 mg oral as a single dose or azithromycin 2 g as a single oral dose [Ib; B].

**Therapy for upper genital tract gonococcal infection**

**Gonococcal epididymo-orchitis**

Recommended treatments when gonorrhoea is diagnosed in a man with acute epididymo-orchitis:

- Ceftriaxone 500 mg intramuscularly as a single dose together with doxycycline 100 mg oral dose twice daily for 10–14 days [IV; C].
- Ciprofloxacin 500 mg as a single oral dose may be used as an alternative to ceftriaxone when sensitivity confirmed by appropriate laboratory susceptibility testing.

(see also European Guideline on Epididymo-orchitis)

**Gonococcal PID**

Recommended treatments when gonorrhoea is the suspected/possible cause of PID:

- Ceftriaxone 500 mg intramuscularly as a single dose together with doxycycline 100 mg oral dose twice daily together with metronidazole 400 mg oral dose twice daily for 14 days [IV; C].

(see also European Guideline on Pelvic Infection).

**Therapy for DGI**

There have been no clinical trials on the treatment of DGI since the progressive development of antimicrobial resistance by *N. gonorrhoeae*. Treatment is based on current antimicrobial sensitivity data, observational data from case series and the principals of treating septicaemia. Hospitalization is recommended for initial therapy.11,12,57,59,81,82

Recommended treatment [IV; C]:

**Initial therapy:**

1. Ceftriaxone 1 g intramuscularly or intravenously every 24 hours.
2. Spectinomycin 2 g intramuscularly every 12 hours.

Therapy should continue for seven days, but may be switched 24–48 hours after symptoms improve to one of the following oral regimens:

- Cefixime 400 mg oral dose twice daily or if fluoroquinolone sensitivity is confirmed by appropriate laboratory susceptibility testing, ciprofloxacin 500 mg oral dose or ofloxacin 400 mg oral dose, twice daily.

**Therapy for gonococcal conjunctivitis**

A three-day systemic regimen is recommended as the cornea may be involved and is relatively avascular [IV; C].57 The eye should be irrigated with sterile saline solution once.

- Ceftriaxone 500 mg intramuscularly as a single dose daily for three days.
- If history of penicillin anaphylaxis or cephalosporin allergy:

Spectinomycin 2 g intramuscularly as a single dose daily for three days.

Or, if antibiotic susceptibility testing at laboratory has excluded resistance:

Azithromycin 2 g oral as a single dose together with doxycycline 100 mg oral dose twice daily for one week together with ciprofloxacin 250 mg oral dose daily for three days [IV; C]

**Therapy for ophthalmia neonatorum (gonococcal neonatal conjunctivitis)**58

The eye should be irrigated frequently with sterile saline solution.

- Ceftriaxone 25–50 mg/kg intravenously or intramuscularly as a single dose, not to exceed 125 mg

**CONTACT TRACING AND MANAGEMENT OF SEX PARTNER(S)**

- Sex partners should be contacted and offered testing together with treatment and counselling for gonorrhoea and chlamydial infection [IV; C];
- For cases of gonorrhoea, all sex partners within the preceding 60 days of onset of symptoms or diagnosis should be evaluated and treated [IV; C].57–60 If a patient’s last sexual contact was more than 60 days prior to their diagnosis, their last sexual partner should be evaluated.

**FOLLOW-UP AND TEST OF CURE**

- Assessment after treatment is recommended to confirm compliance with therapy, resolution of symptoms and signs, exclude re-infection and ensure partner notification [IV; C];
- A test of cure is recommended in all cases to identify persisting infection and emerging resistance.16 Test of cure is particularly important to perform to ensure effective eradication of pharyngeal infection, which is substantially harder to treat than genital and anorectal infections.56–60,71,72 When symptoms persist after treatment, culture is recommended to identify persisting infection and for antimicrobial sensitivity testing and may be performed 3–7 days after completion of therapy, possibly supplemented a week later with a NAAT for increased sensitivity if culture is negative. Tests of cure in asymptomatic patients can be performed with a NAAT two weeks after completion of treatment and ideally, all positives should be cultured and antibiotic susceptibility testing performed before further treatment is given [IV; C].53,84

**IDENTIFICATION, CONFIRMATION AND REPORTING OF TREATMENT failures**

The importance of identification, confirmation and reporting of failures with recommended treatment regimens is stressed.
and described in detail in the recently published WHO Global Action Plan,10 ECDC European Response Plan11 and US CDC Response Plan.12 Ideally, as much clinical and laboratory data as possible should be collected and reported on treatment failures, including a detailed clinical history (including all antimicrobial treatments given), the exclusion of reinfection, highly discriminative molecular epidemiological typing of pretreatment and post-treatment gonococcal isolates/NAAT sample (identifying indistinguishable isolates/genetic variant) and phenotypic susceptibility and genetic susceptibility (isolates contain genetic resistance determinants) in the gonococcal isolates to the used treatment. For details regarding identification, confirmation and reporting of treatment failures in Europe, see the ECDC Response Plan.13

NOTIFICATION
Infections with N. gonorrhoeae should be notified to local, regional and national authorities as mandated by statute. The ECDC is responsible for the European Union-wide surveillance of communicable diseases including gonorrhoea.

ACKNOWLEDGEMENTS
We are grateful for valuable input on the present guideline to David Barlow, Marco Cusini, Mikhail Gomberg, Catherine Ison, Michel Janier, Jørgen Skov Jensen, Lali Khotenashvili, Harald Møi, Raj Patel, Keith Radcliffe, Jonathan Ross, Jackie Sherrard, George-Sorin Tiplica, Angelica Stary, Marita van de Laar.

REFERENCES
14 Taylor SN, DiCarlo RP, Martin DH. Comparison of methylene blue/gentian violet stain to Gram's stain for the rapid diagnosis of gonococcal urethritis in men. Sex Transm Dis 2011;38:955–6
25 Schachter J, Chernesky MA, Willis DE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis 2005;32:725–8
26 Ison C. GC NAATs: is the time right? Sex Transm Infect 2006;82:515
33 Ota KV, Tamari IE, Snieja M, et al. Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in pharyngeal and rectal specimens using the BD ProbeTec ET system, the Gen-Probe APTIMA Combo 2 assay and culture. Sex Transm Infect 2009;85:182–6
34 Alexander S. The challenges of detecting gonorrhoea and chlamydial in rectal and pharyngeal sites: could we, should we, be doing more? Sex Transm Infect 2009;85:159–60

International Journal of STD & AIDS Volume 24 February 2013

Downloaded from std.sagepub.com at Oregon County Council PARENT on May 28, 2013
APPENDIX A

LEVELS OF EVIDENCE AND GRADING OF RECOMMENDATIONS

Levels of evidence

Ia Evidence obtained from meta-analysis of randomized controlled trials.

Ib Evidence obtained from at least one randomized controlled trial.

IIa Evidence obtained from at least one well-designed study without randomization.

IIb Evidence obtained from at least one other type of well-designed quasi-experimental study.

III Evidence obtained from well-designed non-experimental descriptive studies such as comparative studies, correlation studies, and case-control studies.

IV Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities.

Grading of recommendations

A (Evidence levels Ia, Ib). Requires at least one randomized controlled trial as part of the body of literature of overall good quality and consistency addressing the specific recommendation.

B (Evidence levels IIa, IIb, III). Requires availability of well conducted clinical studies but no randomized clinical trials on the topic of recommendation.

C (Evidence IV). Requires evidence from expert committee reports or opinions and/or clinical experience of respected authorities. Indicates absence of directly applicable studies of good quality.

QUALIFYING STATEMENT

Decisions to follow these recommendations must be based on professional clinical judgement, consideration of individual patient circumstances and available resources. All possible care has been undertaken to ensure publication of the correct dosage of medication and route of administration. However, it remains the responsibility of the prescribing clinician to ensure the accuracy and appropriateness of the medication they prescribe.

SEARCH STRATEGY

A Medline search was conducted in May 2012 using PubMed for articles published since the development of the second European guideline on the management of gonorrhoea in adults in 2008 (published in 2009). Search headings were kept broad (gonorrhoea and Neisseria gonorrhoeae) to include epidemiology, diagnosis, antimicrobial resistance, drug therapy, clinical trials and prevention and control. Only publications and abstracts in the English language were considered. The Cochrane library was searched for all entries related to gonorrhoea. Sexually transmitted diseases guidelines produced by the US Centers for Disease Control (www.cdc.gov/std/) and the British Association for Sexual Health and HIV (www.bashh.org) were also reviewed.

EDITORIAL BOARD

Keith Radcliffe (Editor-in-Chief); Karen Babayan, Simon Barton (UEMS), Marco Cusini, Mikhail Gomberg, Michel Janier, Jørgen Skov Jensen, Lali Khotenashvili (WHO), Harald Moi, Martino Neumann (EDF), Raj Patel, Jonathan Ross, Jackie Sherrard, George-Sorin Tiplica (EADV, EDF), Magnus Unemo, Marita van de Laar (ECDC), Willem van der Meijden.

LIST OF CONTRIBUTING ORGANIZATIONS

This guideline has been produced on behalf of the following organizations: the European Branch of the International Union against Sexually Transmitted Infections (IUSTI Europe); the European Academy of Dermatology and Venereology (EADV); the European Dermatology Forum (EDF); the Union of European Medical Specialists (UEMS). The European Centre for Disease Prevention and Control (ECDC) and the European Office of the World Health Organization (WHO-Europe) also contributed to its development.